Clearside Biomedical, Inc.CLSDNASDAQ
Loading
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +20.84% | -95.18% | +913.04% | +446.67% | -80.64% |
| Gross Profit Growth | +44.77% | -97.52% | +930.69% | +353.33% | -80.64% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +20.59% | +21.55% | +10.12% | +4.17% | +5.04% |
| Weighted Average Shares Diluted Growth | +20.59% | +21.55% | +10.12% | +4.17% | +5.04% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | -1161.41% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | -1619.47% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -10.66% | +198.24% | +0.00% | +0.00% | -66.24% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -15.28% | -26.14% | -51.00% | -54.82% | -60.08% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Debt Growth | +4501.57% | +22.02% | +19.26% | -98.88% | -99.11% |
| R&D Expense Growth | -19.59% | -32.56% | -20.12% | -65.59% | -28.95% |
| SG&A Expenses Growth | +7.85% | +3.90% | +0.00% | -19.53% | +51.48% |